The present disclosure relates generally to small molecule inhibitors of axonal degeneration, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
本发明提供了化合物、其组合物以及使用这些化合物用于抑制HPK1和治疗HPK1介导的疾病的方法。
Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists
申请人:Nimbus Saturn, Inc.
公开号:US11078201B2
公开(公告)日:2021-08-03
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
本发明提供了用于抑制 HPK1 和治疗 HPK1 介导的疾病的化合物、其组合物和使用方法。
Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
申请人:Nimbus Saturn, Inc.
公开号:US11021481B2
公开(公告)日:2021-06-01
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
本发明提供了用于抑制 HPK1 和治疗 HPK1 介导的疾病的化合物、其组合物和使用方法。
Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists
申请人:Nimbus Saturn, Inc.
公开号:US11028085B2
公开(公告)日:2021-06-08
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
本发明提供了用于抑制 HPK1 和治疗 HPK1 介导的疾病的化合物、其组合物和使用方法。
Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
申请人:Nimbus Saturn, Inc.
公开号:US11034694B2
公开(公告)日:2021-06-15
The present invention provides compounds of formula I:
or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof. The present invention also provides methods for the inhibition of HPK1 and methods for the treatment of HPK1-mediated disorders.
本发明提供了式 I 的化合物:
或其药学上可接受的盐和/或药物组合物。本发明还提供了抑制 HPK1 的方法和治疗 HPK1 介导的疾病的方法。